Loading...
•
Sep 27, 2025
Hologic Q4 2025 Earnings Report
Hologic reported strong financial results for the fourth quarter of fiscal 2025, with revenue growth and increased GAAP and non-GAAP diluted EPS.
Key Takeaways
Hologic delivered a robust performance in the fourth quarter of fiscal 2025, with total revenue reaching $1,049.5 million, marking a 6.2% increase year-over-year. Both GAAP and non-GAAP diluted EPS saw significant growth, rising by 9.2% and 11.9% respectively. The company also generated strong cash flow from operations and maintained a healthy financial position.
Revenue for Q4 2025 increased by 6.2% to $1,049.5 million, demonstrating solid top-line growth.
GAAP diluted EPS grew by 9.2% to $0.83, and non-GAAP diluted EPS increased by 11.9% to $1.13, reflecting improved profitability.
Diagnostics revenue grew by 2.4% to $454.1 million, driven by core U.S. molecular diagnostics sales despite lower COVID-19 assay sales.
Breast Health revenue increased by 4.8% to $393.7 million, primarily due to strong interventional product sales and improved U.S. sales execution.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Hologic is not providing annual or quarterly financial guidance for fiscal year 2026 due to the pending acquisition by Blackstone and TPG.
Positive Outlook
- The company has entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG, valued at up to $79 per share.
- Strong cash flow from operations of $355.1 million in the fourth quarter.
- FDA clearance and CE marking for Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays indicate continued product innovation.
- Adjusted EBITDA increased by 7.2% to $347.0 million.
- The company ended the quarter with a healthy cash and cash equivalents balance of $1.96 billion.
Challenges Ahead
- No financial guidance provided for fiscal year 2026 due to the pending acquisition.
- GAAP gross margin decreased by 90 basis points, primarily due to expenses associated with closing the Manchester, England manufacturing facility.
- Non-GAAP gross margin decreased by 60 basis points, primarily due to product mix and increased tariff expenses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...